How does the CSL (ASX:CSL) share price perform during lockdowns?

As Australia remains locked down, how can we expect the ASX biotech share to perform?

| More on:
ResMed share price healthcare asx share price flat represented by doctor shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price edged 0.36% lower to close at $296.87 on Monday. Shares in the Aussie biotech have managed to climb higher so far in 2021 but have still underperformed the S&P/ASX 200 Index (ASX: XJO) thus far.

With vast swathes of Australia currently subject to tight COVID-19 restrictions, let's see how one of Australia's largest companies has changed in value throughout previous lockdowns.

What happens to the CSL share price during lockdowns?

Let's wind the clock back to February 2020. As COVID-19 spread across the world, most Aussie shares were in freefall in the March bear market. CSL was not immune from the downturn and fell 19.5% from 20 February to 20 March.

The CSL share price largely recovered and hit $329.00 per share by April 2020. Since then, however, share price growth has been subdued.

Let's consider recent lockdowns and how the ASX biotech share has performed in those times. For instance, Melbourne was subject to strict lockdown orders from August to October 2020.

The ASX biotech share did manage to climb 6.5% from the start of August to the end of October. It's easy to think then that the CSL share price performs strongly during lockdowns.

However, this period also coincided with CSL announcing a vaccine partnership with the University of Queensland. While lockdowns can be extensive, there can also be many company-specific or macro events that impact share prices during those times.

Sydney's Northern Beaches outbreak started just before Christmas last year. The CSL share price fell 4.8% lower throughout the month of December to close the year at $283.18.

Once again, however, the scrapping of the CSL/University of Queensland vaccine candidate occurred on 12 December and may have had a large impact on the share price.

What about the current Sydney outbreak?

While there have been shorter lockdowns in Perth, Adelaide and Melbourne in the intervening months, let's take a look at the current outbreak in Sydney. The first case in the current outbreak was recorded on 16 June with lockdown restrictions from 24 June.

The CSL share price fell 9.8% from 21 June to 15 July. However, the ASX biotech share is up 7.9% since then to its current $296.87 per share level.

Foolish takeaway

For many companies, it's hard to find direct correlations between share price movements and lockdown restrictions. That's particularly the case for a company as large and varied as CSL, which also has a stake in the COVID-19 effort through its AstraZeneca production contract.

The CSL share price growth has been subdued in 2021. Shares in the Aussie biotech are up 4.16% year to date and 6.21% in the last 12 months. Investors will be watching closely to see where they are headed amid the current eastern seaboard lockdowns.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young office worker is surrounded by peers who are clapping and congratulating her.
Healthcare Shares

Up 140% in 2024, here's why this ASX 200 healthcare stock is making news again today

It’s yet another positive update for this stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »